An updated patent therapeutic agents targeting MMPs

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• Matrix metalloproteinases (MMPs) are implicated in numerous physiological and pathological processes.
• Broad-spectrum MMP inhibitors (MMPIs) have been developed for various diseases, including cancer and inflammatory conditions.
• Limited success of broad-spectrum MMPIs necessitates a deeper understanding of MMP functions and the development of selective inhibitors.

Purpose of the Study:

• To review the challenges in validating MMPs as druggable targets.
• To highlight the physiological and pathological roles of specific MMPs.
• To focus on newly emerging MMPI-based patents, particularly those containing sulfonamide or sulfone motifs.

Main Methods:

• Review of existing literature on MMPs and MMPIs.
• Analysis of recent patents for novel MMPIs.
• Examination of structural characteristics and selectivity profiles of sulfonamide/sulfone-containing MMPIs.

Main Results:

• Identified challenges in MMP target validation for drug development.
• Highlighted the importance of MMP subtype-specific roles in disease.
• Described the pharmaceutical applications and design strategies for novel MMPIs, emphasizing sulfonamide and sulfone motifs.

Conclusions:

• Selective inhibition of specific MMPs is crucial for effective therapeutic strategies.
• Ongoing research into MMP biology and inhibitor design is essential for advancing individualized therapies.
• Novel MMPIs, particularly those with sulfonamide or sulfone structures, offer promising avenues for drug development.